{"id":138239,"date":"2025-07-07T14:30:44","date_gmt":"2025-07-07T18:30:44","guid":{"rendered":"https:\/\/medcitynews.com\/?p=138239"},"modified":"2025-07-09T14:07:27","modified_gmt":"2025-07-09T18:07:27","slug":"kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/","title":{"rendered":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease"},"content":{"rendered":"<p>In the rare disease hereditary angioedema, or HAE, painful swelling attacks can happen anywhere in the body without warning. Drugs are available for acute treatment of these attacks, but they\u2019re all administered by injections or infusions \u2014 burdensome dosing methods, particularly for younger patients. The <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250702871458\/en\/KalVista-Pharmaceuticals-Announces-FDA-Approval-of-EKTERLY-sebetralstat-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema\" target=\"_blank\" rel=\"noopener\">FDA has approved<\/a> a KalVista Pharmaceuticals pill, making it the first oral therapy for treating acute attacks caused by HAE.<\/p>\n<p>The regulatory decision announced Monday covers use of the drug by patients age 12 and older. Known in development as sebetralstat, the pill will be marketed under the brand name Ekterly. The approval comes three weeks later than expected. Last month, Cambridge, Massachusetts-based KalVista disclosed that the FDA would not meet that deadline due to <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250613608281\/en\/KalVista-Pharmaceuticals-Announces-FDA-Will-Not-Meet-PDUFA-Goal-Date-for-Sebetralstat-NDA-for-Hereditary-Angioedema-Due-to-FDA-Resource-Constraints\" target=\"_blank\" rel=\"noopener\">&#8220;FDA resource constraints.&#8221;<\/a>\u00a0 The company said its new product, the biotech\u2019s first, will launch immediately.<\/p>\n<p>\u201cFor the first time, patients have access to an oral on-demand treatment that provides the opportunity to change how and when attacks are treated,\u201d KalVista CEO Ben Palleiko said, speaking during a Monday morning conference call.<\/p>\n<p>HAE is an inherited disorder stemming from a genetic deficiency or dysfunction of C1 esterase inhibitor, a protein that controls other proteins associated with swelling and inflammation. Lacking C1 esterase inhibitor leads to uncontrollable activation of the kallikrein-kinin system, which in turn leads to the swelling attacks characteristic of HAE. These attacks can happen throughout the body. They can become life threatening when they affect a patient\u2019s face and airway.<\/p>\n<p>Drugs currently available for treating acute HAE attacks include two C1 esterase inhibitors, Ruconest from Pharming Group and Berinert from CSL Behring. Takeda Pharmaceutical markets a kallikrein inhibitor, Kalbitor, and a bradykinin inhibitor, Firazyr, both for acute treatment of HAE attacks. All of these drugs are administered via needles. BioCryst Pharmaceuticals markets a once-daily oral inhibitor of kallikrein, a protein that plays a role in HAE swelling attacks. The <a href=\"https:\/\/medcitynews.com\/2025\/06\/biocryst-pharma-sells-european-business-for-rare-disease-drug-in-250m-deal\/\" target=\"_blank\" rel=\"noopener\">BioCryst drug, Orladeyo, is approved only for prevention of HAE attacks<\/a> in patients age 12 and older.<\/p>\n<p>KalVista\u2019s Ekterly is an oral small molecule kallikrein inhibitor. In the Phase 3 test that supported Ekterly\u2019s FDA submission, results showed the drug was faster in achieving symptom relief, reduction in attack severity, and attack resolution compared to a placebo. In an open-label extension study, Ekterly enabled patients to treat their acute HAE attacks in a median of 10 minutes following attack onset. These latest results show symptom relief occurring in a median of 1.3 hours for attacks involving the larynx and abdomen as well as for breakthrough attacks in patients who were receiving long-term HAE prophylactic therapy. The most common adverse reaction reported in clinical testing was a headache.<\/p>\n<p>Ekterly\u2019s prescribing information directs patients to take one dose, consisting of two tablets, at the first sign of an HAE attack. A second two-tablet dose may be taken three hours after the first one, if the initial dose was inadequate or if symptoms return or worsen. KalVista will make Ekterly available in packages containing two doses, or four tablets total. KalVista set a wholesale price of $16,720 per dose, which means a single package costs $33,440. By comparison, other branded products available for acute HAE treatment cost between $11,000 to $17,000 per dose.<\/p>\n<p>\u201cWe\u2019ve priced Ekterly competitive to existing branded therapies in the HAE market,\u201d Chief Commercial Officer Nicole Sweeney said. \u201cWe believe this pricing reflects the innovation we\u2019re bringing to the community and will support broad utilization.\u201d<\/p>\n<p>In a note sent to investors, Leerink Partners analyst Joseph Schwartz said Ekterly\u2019s clean label opens the product up to address a broad population of HAE patients.<\/p>\n<p>\u201cWith the potential to treat an attack with a pill, which has long been the holy grail in HAE, we see the approval of Ekterly as paradigm shifting for the landscape,\u201d Schwartz said. \u201cEkterly offers injectable-like efficacy, while the convenient oral route of administration should allow for earlier treatment and the treatment of all HAE attacks.\u201d<\/p>\n<p>Ekterly is still under regulatory review in Europe and Japan. Leerink projects the drug will achieve about $470 million in peak sales in the U.S. and Europe for acute HAE treatment. The drug could find additional uses treating diseases that benefit from kallikrein inhibition. It could also expand its current label in HAE. KalVista has a pivotal study underway evaluating an orally disintegrating tablet formulation of Ekterly for treating HAE attacks in patients age 2 to 11.<\/p>\n<p>Competition to Ekterly could be coming from Pharvaris, which is in pivotal testing with deucrictibant, a bradykinin B2 receptor antagonist formulated as a once-daily capsule. Pharvaris has two Phase 3 tests underway, one for acute HAE treatment and the other for HAE prophylaxis. The Netherlands-based company has said that deucrictibant\u2019s extended-release formulation enables its drug to maintain therapeutic exposure in the body for more than 24 hours, offering the potential for a high rate of resolution of HAE attacks with a single dose.<\/p>\n<p><em>Photo by KalVista Pharmaceuticals<\/em><\/p>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>KalVista Pharmaceuticals\u2019 Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring.<\/p>\n","protected":false},"author":25932,"featured_media":138240,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,63,123,54],"tags":[12102,52776,6207,45707,45706,19695],"class_list":["post-138239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-daily","category-legal","category-pharma-channel","tag-clinical-trials","tag-ekterly","tag-fda","tag-hereditary-angioedema","tag-kalvista-pharmaceuticals","tag-rare-disease"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News\" \/>\n<meta property=\"og:description\" content=\"KalVista Pharmaceuticals\u2019 Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T18:30:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T18:07:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"843\" \/>\n\t<meta property=\"og:image:height\" content=\"562\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease\",\"datePublished\":\"2025-07-07T18:30:44+00:00\",\"dateModified\":\"2025-07-09T18:07:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\"},\"wordCount\":821,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg\",\"keywords\":[\"Clinical Trials\",\"Ekterly\",\"FDA\",\"hereditary angioedema\",\"KalVista Pharmaceuticals\",\"rare disease\"],\"articleSection\":[\"BioPharma\",\"Daily\",\"Legal\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\",\"url\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\",\"name\":\"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg\",\"datePublished\":\"2025-07-07T18:30:44+00:00\",\"dateModified\":\"2025-07-09T18:07:27+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg\",\"width\":843,\"height\":562},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/","og_locale":"en_US","og_type":"article","og_title":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News","og_description":"KalVista Pharmaceuticals\u2019 Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring.","og_url":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/","og_site_name":"MedCity News","article_published_time":"2025-07-07T18:30:44+00:00","article_modified_time":"2025-07-09T18:07:27+00:00","og_image":[{"width":843,"height":562,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease","datePublished":"2025-07-07T18:30:44+00:00","dateModified":"2025-07-09T18:07:27+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/"},"wordCount":821,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","keywords":["Clinical Trials","Ekterly","FDA","hereditary angioedema","KalVista Pharmaceuticals","rare disease"],"articleSection":["BioPharma","Daily","Legal","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/","url":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/","name":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","datePublished":"2025-07-07T18:30:44+00:00","dateModified":"2025-07-09T18:07:27+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/07\/KalVista_PillPack_resized_cropped.jpg","width":843,"height":562},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2025\/07\/kalvista-fda-approval-ekterly-sebetralstat-swelling-inflammation-hereditary-angioedema-hae-kalv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/138239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=138239"}],"version-history":[{"count":0,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/138239\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/138240"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=138239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=138239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=138239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}